EMIS Insights | India Pharma & Healthcare Sector Report 2022-2023
What does this sample report offer?
India’s battle against COVID-19 took a deadly turn in 2021, with more than 420,000 lives lost in the mid-year wave of infections caused by the Delta variant. Nevertheless, there is some optimism that the worst is over for India’s pharmaceuticals and healthcare sector.
This report provides a comprehensive sector overview, with this sample providing access to:
- Entry modes, segment opportunities and government policy
- External and internal driving forces for the sector
- Medical devices net imports and pharmaceuticals net exports
- Consumer confidence and global positioning
About EMIS Insights
EMIS operates in and reports on countries where high reward goes hand-in-hand with high risk. We bring you time-sensitive, hard-to-get, relevant news, research and analytical data, peer comparisons and more for over 197 emerging markets. Our EMIS Insights Report suite constitutes just a proportion of our deep emerging markets information platform, which you can learn more about
here. Alternatively, explore our pay-as-you-go offerings with our EMIS Insights Industry Reports
here.